0
0
5/15/23 at 11:55am
Organization
Seeking Alpha
Author
Dulan Lokuwithana
41 words
0
Comments
Sarepta Therapeutics (SRPT) climbed ~29% in the pre-market Monday after an FDA panel endorsed its gene therapy SRP-9001 for Duchenne muscular dystrophy. Read more here.
You are the first to view
https://seekingalpha.com/news/3971251-sarepta-stock-jumps-fda-panel-nod-gene-therapy
Create an account
or login to join the discussion